TPS Blog

La estimulación transcraneal por pulsos (TPS®) continúa por el camino del éxito. A principios de junio de 2022, se ha instalado el sistema NEUROLITH® número 100. El último emplazamiento de TPS® es la Klinik Lengg en Zúrich (Suiza). El doctor Bartosz Bujan (director médico de Neurorrehabilitación) es uno de los pioneros de la TPS® en Suiza y ahora ofrece la opción terapéutica para pacientes con demencia tipo Alzheimer. Para celebrar este importante hito y mirar al futuro, el 16 de junio se celebró una pequeña fiesta en las instalaciones de la empresa STORZ MEDICAL.

»Nueva esperanza para los pacientes de Alzheimer: un paciente logra volver a recordar«: El 22 de abril de 2022, la estimulación transcraneal por pulsos (TPS®) con el NEUROLITH® fue el tema principal de la portada de BILD, el periódico de mayor tirada de Alemania (con un alcance de 7,62 millones de lectores, principalmente de edad avanzada).

Otro estudio publicado en febrero de 2022 por Matt et al. (Universidad Médica de Viena, Clínica universitaria de neurología) presentó ahora un subanálisis detallado en el que, basándose en datos neuropsicológicos y de imágenes funcionales, se investigan los posibles efectos antidepresivos de la estimulación transcraneal por pulsos (TPS®) con el Sistema NEUROLITH®.²

Un estudio de Matt et al. (Universidad de Medicina de Viena, Departamento Universitario de Neurología) publicado en enero de 2022 investiga los efectos a largo plazo de la estimulación transcraneal por pulsos (TPS®) con el sistema NEUROLITH® en el cerebro y en el comportamiento de los humanos¹. El estudio aleatorizado, de control simulado y doble ciego proporciona por primera vez pruebas con control simulado de los efectos correspondientes.

La estimulación transcraneal por pulsos (TPS®) se estrena en Ucrania. El 12 de enero de 2022 se instaló el primer sistema NEUROLITH® en la capital cultural de Ucrania occidental, Lwiw (en español Leópolis, con unos 750.000 habitantes). A partir de ahora, los pacientes con Alzheimer pueden someterse a este tratamiento en »BRAINSPOT LVIV«, una clínica de neuromodulación (dirección: Tomas Dzeminskyy, médico jefe: Andrii Hul). Ya se han realizado las primeras sesiones de terapia.

In early January 2022, a study on the development of global dementia prevalence published by the medical journal The Lancet Public Health¹ received a lot of attention. The study predicts that the number of cases will triple to 152.8 million by 2050.The World Alzheimer Report 2019 already came to a similar assessment. The most important factors for this explosive development are the ageing of the global population and its further growth.

It's getting exciting: In the RTL News report »Neue Alzheimer-Therapie: Sanfte Stosswellen bringen Gedächtnis zurück«. Prof. Dr Musa Citak introduces in his practice in Hamburg the NEUROLITH® system and the treatment method, Transcranial Pulse Stimulation – short TPS®.
TPS® as a modern therapy method for the treatment of Alzheimer's dementia stimulates different brain regions even in deeper areas.

Exciting report film on the topic of »shockwave therapy for dementia« was shown last Saturday on »Bewusst Gesund« on ORF 2 (Austrian broadcasting). There our Transcranial Pulse Stimulation (TPS®) was presented in the practice of Dr. Matthias Geisler.

How TPS® works and how successful TPS® is you can see in the film. The film is available for public viewing on ORF TVTHEK:

Transcranial Pulse Stimulation (TPS®) with the NEUROLITH® system is a new therapy option for patients with Alzheimer’s disease that allows targeted stimulation of cerebral regions.

Key-facts:

• TPS® are shock waves which allow highly focal brain stimulation deep in the brain.
• TPS® allows unprecedented precision for targeting brain areas.
  

Transcranial Pulse Stimulation (TPS®) with the NEUROLITH® is increasingly gaining momentum: Since the CE approval for the »treatment of the central nervous system of patients with Alzheimer’s disease« in 2018, more than 50 NEUROLITH® systems have been installed worldwide. In June 2021, three more devices were installed in renowned neurological specialist clinics in Germany, Austria, and Turkey.

One of the highlights of the new NEUROLITH® system is its innovative BodyTrack software – a unique tool for the visualization and control of the TPS® pulses applied and of treatment progress. Real-time tracking of the handpiece position enables automatic visualization of the treated regions. The use of personalized MRI data allows specific characteristics of the patient’s brain to be taken into account.

»Overall, I feel good after the treatment and progress has been made. I notice that I respond well when someone talks to me and find the words to express myself better. In addition, my memory has improved somewhat. When I go shopping, I take the shopping list just to be on the safe side, although I could do without it.

Transcranial Pulse Stimulation (TPS®) with the NEUROLITH® system is performed by a trained practitioner and is done on an outpatient basis. During treatment, the patient sits comfortably in a chair and can move freely at any time. To ensure optimal transmission of the pulses, the therapist applies ultrasound gel to the scalp or hair – it is not necessary to shave the patient’s head. The patient then puts on a pair of special glasses so that the position of the head can be detected.

The authors of a follow-up study (published in 2021) investigated the possible benefits of TPS® treatment concerning brain morphology, namely the cortical atrophy characteristic of Alzheimer’s disease [1]. They found a significant correlation between neuropsychological improvement and cortical thickness increase in AD-critical brain areas.

»Laughing and being happy - for healthy people this is normal. During my TPS® treatments, I notice that this is no longer normal for my patients. Many are sad and seem withdrawn. This is understandable when you can no longer do things the way you used to. I am all the more pleased when relatives call me after the first TPS® treatments with the NEUROLITH® or write to me that their loved ones are now happier again and that they are smiling more often.

In 2019, the clinical approval study for Transcranial Pulse Stimulation (TPS®) with STORZ MEDICAL’s NEUROLITH® system was published in the prestigious journal Advanced Science [1]. Prof. Dr. Beisteiner’s study, which was conducted at the Medical University of Vienna Beisteiner, documents the positive effects of TPS in the treatment of patients with Alzheimer’s dementia.

Aviso: la siguiente publicación y la película mostrada están en alemán.

Im Film »Wie hilft Ultraschall gegen Alzheimer« wird spannend unsere Transkranielle Pulsstimulation (TPS®) vorgestellt.

Also das moderne Therapieverfahren zur Behandlung von Alzheimer-Demenz durch die Stimulation verschiedener Gehirnregionen.

The acoustic pulses generated by Transcranial Pulse Stimulation (TPS®) have been used successfully in various medical fields (urology, orthopaedics, cardiology….) for decades under the term »extracorporeal shock wave therapy«.

Shock waves are similar to ultrasound. But there is a major difference:

In 2018, Transcranial Pulse Stimulation (TPS®) with the NEUROLITH® system was the first, and hitherto only, procedure of its kind to obtain market authorization for the »treatment of the central nervous system of patients with Alzheimer’s disease«. The aim of TPS® is to boost the cognitive abilities of people with Alzheimer’s dementia by stimulating various regions of the brain and to maintain these abilities for as long as possible.